why choose us

First received: February 22, 2023

Clinical Trial: Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Alzheimer Disease

Study Type: INTERVENTIONAL


Official Title: Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Su

Brief Summary: ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.

Read more